MAPK3 and diabetes mellitus: Administration of PARP inhibitor to diabetic rats significantly attenuated diabetes-induced increased expressions of PARP activation, ROS, p-ERK1/2, and cleaved caspase-3 and decreased BDNF, synaptophysin, and GS levels in the retinas.